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(BCLC) A (73.4 months) and B (50.3 months) patients, while 
analyses failed to show a difference for Child-Pugh score, 
Cancer of Liver Italian Program (CLIP) score and tumor distri-
bution pattern.  Conclusion: TACE combined with RFA pro-
vides an effective treatment approach with high local tumor 
control rates and promising survival data, especially for BCLC 
A patients. Randomized trials are needed to compare this 
multimodality approach with a single modality approach for 
early-stage HCC.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Hepatocellular carcinoma (HCC) is considered to be 
one of the major malignant diseases in the world today. It 
is the second leading cause of cancer mortality worldwide 
 [1] and the fifth most common cancer  [2, 3] . The inci-
dence of HCC varies in different geographic areas, de-
pending on the prevalence of the major causes, namely 
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 Abstract 
 Background/Aims: To evaluate the efficacy of multimodal-
ity treatment consisting of conventional transcatheter arte-
rial chemoembolization (TACE) and radiofrequency ablation 
(RFA) in patients with non-resectable and non-ablatable he-
patocellular carcinoma (HCC).  Methods: In this retrospective 
study, 85 consecutive patients with HCC (59 solitary, 29 mul-
tifocal HCC) received TACE followed by RFA between 2001 
and 2010. The mean number of tumors per patient was 1.6 
 8 0.7 with a mean size of 3.0  8 0.9 cm. Both local efficacy 
and patient survival were evaluated.  Results: Of 120 treated 
HCCs, 99 (82.5%) showed a complete response (CR), while in 
21 HCCs (17.5%) a partial response was depicted. Patients 
with solitary HCC revealed CR in 91% (51/56); in patients with 
multifocal HCC (n = 29) CR was achieved in 75% (48 of 64 
HCCs). The median survival for all patients was 25.5 months. 
The 1-, 2-, 3- and 5-year survival rates were 84.6, 58.7, 37.6 and 
14.6%, respectively. Statistical analysis revealed a significant 
difference in survival between Barcelona Clinic Liver Cancer 
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chronic liver disease due to chronic viral hepatitis and 
alcohol-induced liver cirrhosis. Together, hepatitis C vi-
rus and hepatitis B virus account for 80–90% of all HCCs 
worldwide  [4] .
 The incidence of HCC in North America and in Eu-
rope has been increasing in the last decades due to migra-
tion from areas with a high prevalence of HCC and due 
to the epidemic of hepatitis C in North America and Eu-
rope between 1950 and 1970  [5] . Whereas the incidence 
of HCC has increased in the past decades  [6] , only a small 
portion of patients with early-stage HCC can be treated 
curatively with resection or orthotopic liver transplanta-
tion. However, most patients are not candidates for sur-
gery at the time of diagnosis due to either lesion size, 
number of lesions, liver function or comorbidity. Due to 
the advances in medical imaging technology as well as 
minimal invasive, locoregional treatment options, vari-
ous approaches to interventional oncology treatments 
have been developed. Recently published studies have 
shown the efficacy and safety of a wide array of locore-
gional therapies.
 These methods include transcatheter arterial chemo-
embolization (TACE) and radiofrequency ablation (RFA). 
They have gradually played more and more important 
roles in the treatment of HCC  [7] . The superiority of RFA 
over percutaneous ethanol injection has been shown in 
several studies  [8–13] . Other studies reporting on RFA 
indicate that a complete short-term necrosis can be 
achieved in 80–90% of tumors  ! 3–5 cm in diameter  [13–
15] . In very early HCC (Barcelona Clinic Liver Cancer 
(BCLC) classification), RFA can be considered as a val-
uable alternative treatment option to surgical resection, 
especially since RFA is easily repeatable, shows a lower 
morbidity profile, and therefore can be offered to patients 
who refuse surgery or have to be rejected for other medi-
cal conditions  [16, 17] . On the other hand, TACE induces 
an ischemic necrosis by using antitumor drugs and em-
bolizing agents and prolongs survival  [18, 19] . Evidence 
suggests that TACE combined with RFA have a synergis-
tic effect  [20, 21] in treating HCC and is superior to TACE 
or RFA alone in terms of the effect of survival  [22, 23] . 
The decrease of blood flow in the HCC lesion by TACE 
appears to increase the efficacy of RFA in destroying tu-
mors. Especially in lesions  1 5 cm, a combined approach 
of RFA and TACE results in a higher percentage of com-
plete necrosis  [24, 25] . The prognosis of patients with 
HCC depends on tumor status, liver function reserve, 
general health status and efficacy of treatment  [26] . 
 Various prognostic staging systems have been devel-
oped to provide treatment strategies and to determine the 
survival of the patients. The BCLC staging and treatment 
algorithm considers tumor burden, liver function status 
and patient’s physical status providing a stratification of 
patients in different treatment groups  [27] . In Europe the 
BCLC classification is recommended by the European 
Association for the Study of the Liver (EASL)  [26] and the 
American Association for the Study of Liver Diseases 
(AASDL)  [28] , because it is the only validated system that 
includes tumor burden, patient’s performance status and 
liver function leading to a stage-related treatment strat-
egy  [29] . Therefore, we applied the BCLC score for the 
stratification of the patients in our analysis.
 The aim of this retrospective analysis was to deter-
mine the efficacy of the combined treatment approach by 
evaluating contrast-enhanced CT/MR scans for the as-
sessment of local tumor control and to evaluate survival 
rates of HCC patients stratified by BCLC, Child-Pugh, 
Cancer of Liver Italian Program (CLIP) and tumor dis-
tribution.
Table 1.  Patients’ characteristics
Patients, n 85
Gender (male/female) 68/17
Mean age 8 SD, years 65.989.1
Child-Pugh score
Class A 80
Class B 5
 Barcelona Clinic Liver Cancer
Stage A 65
Stage B 20
Cancer of Liver Italian Program 50
Score 0
Score 1 35
Tumor distribution among patients, n
Solitary 56
Multifocal 29
Number of tumors
1 56 (65.9%)
2 17 (20%)
3 9 (10.5%)
4 2 (2.4%)
5 1 (1.2%)
Follow-up (mean 8 SD), months 2–74 (22.5814)
Treated HCCs 120
Number/patient 8 SD 1.480.57
Lesion diameter (mean 8 SD), mm 7–60 (2589)
Etiology of cirrhosis, n
Hepatitis C virus 34
Hepatitis B virus 8
Alcohol 25
Others 18
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 Patients and Methods 
 Patients 
 Between April 2001 and May 2010, 85 consecutive patients 
with HCC (68 men, 17 women; age 41–92 years, mean 65  8 9.1) 
were treated with combined therapy (conventional TACE fol-
lowed by RFA). Details are presented in  table 1 . Out of the 85 pa-
tients, 60 met the Milan criteria. Of 60 patients, 44 were listed for 
liver transplantation. The remaining 16 patients had comorbidi-
ties like coronary heart disease (n = 6), a second malignant disease 
(n = 7) or COPD with pulmonary hypertension (n = 3). The inten-
tion to treat the listed patients was to avoid a dropout from the 
waiting list. For the 25 patients not listed, the combined therapy 
targeted at downstaging the patients. The remaining 16 patients 
with severe comorbidities were treated palliatively. Due to their 
comorbidities they were both withdrawn from the transplanta-
tion list and also refused a surgical approach, so a palliative treat-
ment approach was the only alternative, although these 16 pa-
tients met the Milan criteria. The hepatic function was deter-
mined for each patient utilizing the Child-Pugh scoring system. 
80 patients presented with Child-Pugh A cirrhosis and 5 patients 
with Child-Pugh B cirrhosis. A prerequisite for locoregional 
treatment was a sufficient blood clotting status with a PTT  ! 40 s, 
INR  ! 1.75, and a platelet count  1 40,000/mm 3 .
 As part of the pretreatment workup, CT examinations with a 
multiphasic protocol (contrast flow rate 5 ml/s (unenhanced, arte-
rial, portal-venous and late phases)) were performed in each pa-
tient using multidetector scanners (Somatom Sensation 16 and 64, 
Somatom Definition, Somatom Definition Flash and Somatom 
Definition AS+; Siemens, Forchheim, Germany). Also an MRI ex-
amination was frequently performed as a pretreatment workup 
and especially during the follow-up ( fig. 1 a, h). The contrast-en-
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 Fig. 1.  a – f 73-year-old patient with hepati-
tis-C-induced liver cirrhosis and with a 
solitary HCC in liver segment 8. The con-
trast-enhanced T 1 W GRE sequence re-
veals arterial enhancement of the HCC le-
sion ( a ). Angiography before ( b ) and after 
( c ) TACE. RFA after 2 days ( d – f ). First fol-
low-up 24 h after RFA with heterogeneous 
uptake of iodized oil in the central aspect 
of the lesion surrounded by an ablation 
rim ( g ). Follow-up MRI after 6 weeks re-
veals CR without arterial contrast uptake 
within the lesion ( h ). 
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hanced MRI examinations (Gd-EOB-DTPA Dinatrium (Primo-
vist  )/Ferucarbotran (Resovist  , until 2007)) were performed in 
high-field scanners (Magnetom Sonata (1.5 T), Magnetom Avanto 
(1.5 T) and Magnetom Verio (3 T); Siemens) and were among oth-
ers composed of a dynamic phase and accumulation phase.
 MRI was performed as a pretreatment workup in 36 patients 
(42.4%) and especially during the follow-up after 6–8 weeks in 77 
patients (90.6%). The diagnosis of HCC was confirmed either by 
biopsy or by imaging techniques ( fig.1 a) according to the Euro-
pean Association for Study of the Liver consensus conference cri-
teria  [26] . Prior to the combined treatment approach, 56 patients 
presented with a single HCC manifestation while 29 had multi-
nodular disease with a maximum of 5 lesions. Infiltrating HCC 
or portal vein thrombosis were exclusion criteria for this retro-
spective evaluation. Other exclusion criteria were an Eastern Co-
operative Oncology Group performance status  1 2  [30] or ad-
vanced/terminal tumor stage according to the BCLC classifica-
tion. 
 According to the BCLC classification, 65 patients presented 
with early-stage HCC (BCLC A) while 20 patients were stratified 
as BCLC B patients (intermediate stage HCC). BCLC B patients 
were considered eligible for combined locoregional treatment if 
HCC lesions were deemed accessible for image-guided placement 
of the RFA device. The total number of HCCs in all patients was 
132. However, 12 lesions were not treated by the combined locore-
gional treatment approach due to their anatomical location (7), 
inadequate visualization in CT (2) or due to patients’ comorbidi-
ties or other complications (3). However, the mean number of 
HCC nodules per patient was 1.6  8 0.7.
 The maximum diameter of the 120 treated lesions varied from 
0.7 to 6.0 cm (mean 2.5  8 0.9, median 2.5). The sum of the max-
imum diameter of all HCCs per patient ranged from 1.1 to 10.5 
cm (mean 3.8, median 3.4). 39 of the treated HCCs were  ! 2 cm 
(32.5%), whereas 81 were  1 2 cm (67.5%). Written informed con-
sent was obtained from all patients before treatment.
 Conventional Transcatheter Arterial Chemoembolization 
 In each patient, prior to RFA a conventional lipiodol-based 
(max. 10 cm 3 ) TACE with a chemotherapeutic drug (epirubicin 
hydrochloride) was performed. Calibrated microspheres (diam-
eter 250   m) were added in those patients where the lipiodol did 
not devascularize the HCC nodule completely.
 Under angiographic control (Polystar Angio Suite, Axiom Ar-
tis dTA, Axiom Artis Zeego; Siemens), first a 4-Fr angiographic 
catheter (pigtail configuration) was inserted through the femoral 
artery in the aorta to perform a mapping angiography of the liv-
er-supplying arteries. After the intubation of the superior mesen-
teric artery and the common hepatic artery by switching to a co-
bra or sidewinder configuration (4 Fr), a superselective catheter-
ization of the hepatic arteries and the superior mesenteric artery 
was performed. In all cases patency of the portal vein was verified 
by acquiring a portal venogram after injection of contrast in ei-
ther the splenic or superior mesenteric artery. After superselective 
catheterization of the hepatic and tumor-feeding arteries utiliz-
ing a coaxial technique and microcatheters (2.7 Fr, Progreat  ; 
Terumo, Leuven, Belgium;  fig. 1 b) an emulsion consisting of 50 
mg epirubicin hydrochloride (Farmorubicin  ; Pfizer Pharma) 
and max. 5 cm 3 iodized oil (Lipiodol Ultra-Fluid  ; Guerbet) were 
slowly infused under fluoroscopic guidance until stasis within the 
HCC lesion or the tumor-feeding vessel was reached ( fig. 1 c). Cal-
ibrated polyvinyl alcohol particles (BeadBlock  ; Biocompatibles 
International, Farnham, UK) or other microspheres (Embozene  ; 
Celonova Biosciences, Atlanta, Ga., USA) were applied to achieve 
complete stasis in the tumor if necessary. Patients were carefully 
observed during the entire procedure, and analgesics and anti-
emetics were administered on demand.
 Radiofrequency Ablation 
 After multiphase contrast-enhanced computed tomography 
(CT) was performed, the optimal electrode pathway to the HCC 
lesion was determined. All RF ablation procedures were per-
formed using multitined expandable electrodes (Starburst  XL, 
Xli, Talon; AngioDynamics, Cambridge, UK/LeVeen  needle 
electrode; Boston Scientific, Ratingen, Germany). With this elec-
trode design, an array of multiple, stiff, curved wires was deployed 
in the HCC and distended to its maximum diameter of 2–5 cm. 
The electrodes were placed under CT-/CT-fluoroscopy and occa-
sionally ultrasound guidance (Sonoline Elegra, Sonoline Prima 
Acuson S 2000; Siemens). In cases of HCC nodules with critical 
anatomical locations or lesions that are not amenable to ultra-
sound, a CT-fluoroscopy guidance (Somatom Sensation 4, 16, 64, 
Somatom Definition AS+; Siemens) was performed.
 The exact positioning of the electrode and the complete cover-
age of the lesion with the hooks fully distended was warranted by 
CT-/CT-fluoroscopy guidance ( fig. 2 c), or when there was doubt, 
with additional contrast-enhanced CT scans. After attaching to 
the high-power RF generator the RF current was emitted from the 
active, non-insulated curved electrodes. The delivered power was 
increased until the target temperature of 95–100  °  C was reached. 
Subsequently, the energy was maintained as long as 20–45 min. 
When the LeVeen  system was used, energy was applied until an 
increase of impedance was noted twice indicating complete co-
agulation necrosis. To control the achieved coagulation zone in-
stantaneously after completing the procedure, a postprocedural 
contrast-enhanced CT scan with the electrode still in place was 
performed to depict incomplete ablation with the option of an im-
mediate additional ablation as well as to detect potential peripro-
cedural complications. For HCCs  ! 3 cm in size, a single session 
of ablation with a maximum electrode diameter of 5 cm was used 
to provide a sufficient safety margin. In larger lesions, the elec-
trode was repositioned several times in a single session in order 
to achieve a volume large enough to cover the entire HCC includ-
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 Fig. 2. Kaplan-Meier survival curve after the combined therapy 
for all patients. 
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ing a safety margin. To reduce the risk of puncture-related bleed-
ing, electrode-track ablation was performed after completion of 
the procedure at a reduced power level. Our standard approach 
for RF ablation was to perform the procedure under moderate se-
dation and local anesthesia. The majority of ablations were per-
formed with administration of a combination of midazolam ma-
leate, parecoxib sodium and piritramide. Blood pressure, heart 
rate and oxygen saturation were monitored continuously. In pa-
tients who presented with low tolerance to pain, or lesions that 
were difficult to target, the procedure was performed under gen-
eral anesthesia. Preinterventional antibiotics were used for all pa-
tients.
 Local Efficacy 
 During the follow-up imaging examinations mostly by con-
trast-enhanced MRI, the treated HCC nodules were stratified ac-
cording to the modified RECIST criteria  [31] into complete re-
sponse (CR), partial response (PR), stable disease (SD) and pro-
gressive disease (PD).
 Statistical Analysis 
 Continuous survival data are displayed as mean  8 standard 
deviation and as proportions for binary data. Survival curves and 
median survival as well as pertaining 95% confidence intervals 
(CI) were estimated by the Kaplan-Meier method and group com-
parisons were made by log-rank test statistics. Patients on the 
waiting list for the liver transplantation were censored at the time 
of transplantation. All analyses were performed by SAS version 
9.2 (SAS Institute Inc., Cary, N.C., USA) and a two-sided p value 
 ! 0.05 was considered to indicate statistical significance.
 Results 
 The median duration of follow-up after combined 
treatment was 16 months (range 2–74). The mean patient 
age was 66 years (range 42–93). The mean number of 
HCC lesions per patient was 1.6 with a range of 1–5 le-
sions. The mean diameter (sum of maximum diameter of 
HCCs per patient) of the treated lesions was 3.8 cm (range 
1.1–10.5). RFA were performed after a median time of 1 
day after TACE (range 1–20, mean 3.8).
 According to the Society of Interventional Radiology 
guidelines, no major complications were observed. The 
most common postprocedure morbidity was postembo-
lization syndrome, consisting of fatigue, mild nausea, 
low-grade fever, and abdominal pain that were easily 
managed with oral narcotics and antiemetics. In 8% of 
the cases, there was a slight subcapsular bleeding after 
RFA with neither clinical symptoms nor progression in 
an additional CT scan performed the day after RFA.
 Until the end of the study, 13 patients of the listed pa-
tients were transplanted whereas 4 patients were removed 
from the waiting list due to tumor progression or death. 
Of these 4 patients, 1 died due to liver failure; the 3 re-
maining patients were removed from the waiting list ow-
ing to tumor progression with intrahepatic distant new 
HCC nodules.
 Efficacy of Combined Treatment (TACE + RFA) 
 The efficacy was determined using contrast-enhanced 
CT or MR scans obtained 6–8 weeks and then every 3 
months after combined locoregional therapy ( fig. 1 h). In 
99 of 120 lesions (82.5%) and in 70 of 85 patients (82.3%), 
the first follow-up using CT/MRI 6–8 weeks after com-
bined treatment revealed CR. Lesion diameter at the time 
of treatment ranged from 0.7 to 6.0 cm (mean 2.5  8 0.9, 
median 2.5). In 21 of 120 lesions (17.5%; 15 patients), the 
follow-up displayed a PR. In this subgroup the lesion di-
ameter ranged from 0.7 to 5.0 cm (mean 2.8  8 0.9, me-
dian 2.5). There was no statistical significant difference 
regarding the maximum diameter between groups.
 When response was analyzed for patients who had a 
solitary HCC, CR was achieved in 51 of 56 (91%) lesions 
with a PR in the remaining 5 (9%) lesions. For the 64 le-
sions treated in our 29 patients with multifocal tumor, 
MRI indicated CR in 48/64 (75%) while there was PR in 
16/64 (25%). When analyzed, the difference in CR ob-
served between the two groups (single lesion vs. multiple 
lesions) was significant (p  ! 0.05). During follow-up 
(mean 16 months, range 2–74), CR was maintained in 
93/120 (77.5%) of the HCCs.
 In lesions with a diameter  ! 5 cm, CR was maintained 
over time in 88/111 (79%) while 23/111 (21%) showed PR. 
Among the 9 HCCs with a diameter  6 5 cm, only 5/9 
(55%) revealed CR while 4/9 (45%) did show residual tu-
mor. CR was maintained during follow-up in 44 out 56 
HCCs in the 56 patients who initially presented with sol-
itary HCC, while in the 29 patients with multifocal dis-
ease CR was maintained only in 48 out of 64 HCCs.
 Survival 
 Overall Survival 
 Survival curves were evaluated using the Kaplan-Mei-
er method. The median survival rate for all patients, with 
calculation started on the date of RF ablation, was 25.5 
months (95% CI 23–35%) ( fig. 2 ). The 1-, 2-, 3- and 5-year 
survival rates were 84.6% (95% CI 77–92), 58.7% (95% CI 
48–69), 37.6% (95% CI 27–48) and 14.6% (95% CI 6–23), 
respectively.
 Prognostic Value of BCLC Stage 
 There was a statistically significant difference in the 
survival probability of patients with BCLC A (n = 52) and 
BCLC B (n = 20) patients (log-rank test, p = 0.0334) 
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( fig. 3 ). The median survival durations were 73.4 and 50.3 
months for BCLC A and BCLC B patients, respectively.
 Prognostic Value of Child-Pugh Score 
 There was no statistically significant difference in sur-
vival between patients with Child-Pugh A (n = 67) and 
Child-Pugh B (n = 5) liver cirrhosis (log-rank test, p = 
0.92) ( fig. 4 ). The median survival duration was 73 months 
in Child-Pugh A patients. For the subgroup of Child-
Pugh B, median survival was not calculated as the num-
ber of patients with Child-Pugh B (5) was limited.
 Prognostic Value of CLIP Score 
 A separate Kaplan-Meier evaluation of patients with a 
CLIP score of 0 (n = 42) or 1 (n = 30) ( fig. 5 ) revealed sub-
stantially different survival rates but failed to demon-
strate statistical significance (log-rank test, p = 0.64). The 
median survival durations for patients with CLIP 0 and 
CLIP 1 were 73 and 49 months, respectively.
 Prognostic Value of Tumor Distribution 
 There was no statistically significant difference in the 
survival probability of patients with solitary (n = 48) and 
multifocal HCC (n = 24) (log-rank test, p = 0.6318) ( fig. 6 ). 
The median survival durations were 73.4 and 59.3 months 
for patients with solitary and multifocal HCC, respec-
tively.
 Discussion 
 Since the rate of complete necrosis in RFA decreases as 
tumor size increases, combining RFA with therapies that 
occlude arterial supply or other local ablative therapy has 
been proposed and studied to increase the area of coagu-
lative necrosis. Researchers hypothesized that blood flow 
occlusion in the tumor can decrease heat dispersion by 
the bloodstream, and increase the size of the necrotic
area produced with ablation  [21, 32] . 
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 Fig. 3. Kaplan-Meier survival curve of patients with BCLC A and 
BCLC B HCC with a significant difference in the survival prob-
ability (p = 0.0334). 
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 Fig. 4. Kaplan-Meier survival curve depicts no statistically sig-
nificant difference in survival between patients with Child-Pugh 
A and Child-Pugh B (liver cirrhosis; p = 0.92). 
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 Fig. 5. Kaplan-Meier survival curve of patients with a CLIP score 
of 0 and 1 without a statistically significance difference (p = 0.64). 
 Fig. 6. Kaplan-Meier survival curve of patients with solitary and 
multifocal HCC failed to show a significant difference between 
the two groups (p = 0.6318). 
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 In this connection the question arises how TACE and 
RFA should be sequenced. The advantage of TACE prior 
to RFA is as previously mentioned the reduced heat sink 
effect with the ability to create larger ablation zones more 
easily. The advantage of using TACE after RFA is that 
RFA generates a hyperemic rim surrounding the ablation 
areas, which can then consequently be targeted by trans-
arterial means more effectively. Further studies need to 
clarify how locoregional treatment options should be im-
plemented in the treatment paradigm of non-resectable 
HCC. However, the efficacy of the combined therapy 
with TACE preceding RFA has been shown in several pre-
vious studies. In a study by Buscarini et al.  [33] involving 
14 patients affected by HCC (mean diameter 5.2 cm), the 
efficacy of combined therapy consisting of RFA and 
TACE in treatment of HCCs larger than tumors suitable 
for segmental TACE or RF application alone was demon-
strated. In another study, Lencioni et al.  [34] could show 
in a pilot multicenter clinical trial performed in 62 HCC 
patients treated by TACE and RFA a successful ablation 
of HCC lesions (range 3.5–8.5) in 82% of the cases, which 
exactly matches the numbers that we report in this study. 
Veltri et al.  [35] demonstrated in a study in 46 unresect-
able, non-early HCC patients with a total of 51 lesions 
(30–80 mm, mean 48.9), CRs in 66.7% of the lesions. In 
accordance with these previous studies, we report a CR 
rate of 82.5% in the treated HCCs. The difference to the 
CR rate reported by Veltri et al.  [35] may be due to the fact 
that we also included patients with early HCC (BCLC), 
where effective tumor treatment might be easier to ac-
complish. Among other prognostic factors (pretreatment 
of the lesions, lesion diameter), we investigated the influ-
ence of multifocality on the local result following combi-
nation therapy. In our study, the percentage of CR in sol-
itary HCC (91%) is significantly higher than in multifocal 
tumors (75%).
 Statistical analysis shows that HCC lesions  1 50 mm 
are more difficult to treat, as reported in the literature 
 [24, 25, 36] . However, due to the small number of HCCs 
 1 5 cm included in this analysis, final conclusions are dif-
ficult to derive. Anyhow, consistent with published re-
sults, our statistical analysis further showed that during 
the follow-up CR was maintained in 79% of lesions with 
a diameter  ! 5 cm, whereas CR was maintained in the 
follow-up in only 55% of lesions with a diameter  6 5 cm. 
These results are well in line with previously published 
studies. With respect to lesion size, Rossi et al.  [20] re-
ported a 90% positive outcome in 62 cirrhotic patients 
with HCC with a mean diameter of 47 mm (interval 35–
85 mm) treated with combined therapy. In another study, 
Veltri et al.  [35] showed a CR in 85% of patients with le-
sions  ! 5 cm.
 Similar results to our study are depicted in a retrospec-
tive study by Kim et al.  [37] with tumor progression rates 
of 16% with TACE + RFA during a follow-up time of 37 
months in single small ( ! 3 cm) HCC nodules. Kim et al. 
 [38] depicted in single intermediate-sized (3.1–5.0 cm) 
HCCs with a tumor progression rate of 40% for TACE + 
RFA and 70% of RFA alone also superiority in favor of the 
combined treatment approach.
 Regarding clinical results, TACE is considered a mid-
term effective therapy for non-operable HCC. The im-
pact of this procedure on survival of patients with inter-
mediate-advanced HCC treated with combined therapy 
was evaluated in numerous retrospective and prospective 
studies as well as in meta-analyses which have shown 
promising results  [39, 40] . However, a recent meta-analy-
sis has suggested that there is no statistically significant 
difference in survival at 3 and 6 months between patients 
treated with this procedure and patients treated with oth-
er palliative procedures  [41] .
 In our study, the 1-, 2-, 3- and 5-year survival rates 
were 84.6, 58.7, 37.6 and 14.6%, respectively. Similarly, 
Veltri et al.  [35] demonstrated 1- and 2-year survival rates 
of 89.7 and 67.1%, respectively. In a study with 62 patients, 
Kagawa et al.  [17] demonstrated that RFA combined with 
TACE is an efficient and safe treatment that provides 
overall survival rates similar to those achieved with sur-
gical resection. These survival rates are higher than the 
survival rates presented in our study or in the study pub-
lished by Veltri et al.  [35] . This might be most likely con-
tributed to a selection bias towards patients with smaller, 
fewer or anatomically favorable tumors. Furthermore, 
differences in the cause of the underlying cirrhosis and 
tumor biology might impact on the patient’s survival. 
This is partly supported by the statistically significant 
difference between the median survival of patients with 
BCLC A (73.4 months) and patients with BCLC B (50.3 
months) in our study, which amplifies the idea the early 
detection and treatment of the tumors will result in in-
creased patient survival. The comparably low overall sur-
vival reported in our study might be explained by the 
following issues: 16 patients with severe comorbidities 
were included in the study. Furthermore, there is a selec-
tion bias against interventional radiology since only pa-
tients who have been rejected from surgery (coronary 
heart disease, COPD, second tumor) have been recruited 
for this multimodality treatment approach.
 In a recent retrospective study, Kim et al.  [37] com-
pared the local efficacy and the overall survival of com-
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